Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD

Research site

Bulgaria Bulevard Gen. Stoletov No 67a, 1233 Sofia, Bulgaria

  • 19 trials recruiting
  • Chronic obstructive pulmonary disease · Asthma · Atrial fibrillation
  • Adults and children

About Specializations

Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD in Sofia, Bulgaria specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Asthma, Atrial fibrillation, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine

The medical center is at the forefront of respiratory medicine, focusing on innovative treatments for Chronic Obstructive Pulmonary Disease (COPD). The center's research is dedicated to improving patient outcomes through advanced therapeutic strategies.

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Astegolimab Efficacy and Safety
  • Reduction of COPD Exacerbations

By conducting pivotal studies, the center contributes significantly to the understanding and management of COPD, aiming to reduce the frequency and severity of exacerbations and enhance the quality of life for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bulevard Gen. Stoletov No 67a1233 SofiaBulgaria
Open in maps ↗
Recruiting now
19 trials
Conditions studied
20

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

45 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Chronic obstructive pulmonary disease

Recruiting

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
  • Sponsor:Pfizer Inc.

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:PF-07328948
  • Sponsor:Pfizer Inc.

Acute respiratory failure

Recruiting

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:BulgariaBulgaria
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Atrial fibrillation

Recruiting

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Bayer AG

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.